{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:00:04Z","timestamp":1791446404357,"version":"4.3.3"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2014,5,19]],"date-time":"2014-05-19T00:00:00Z","timestamp":1400457600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0098315","type":"journal-article","created":{"date-parts":[[2014,5,19]],"date-time":"2014-05-19T20:35:09Z","timestamp":1400531709000},"page":"e98315","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["Anti-CD22\/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus"],"prefix":"10.1371","volume":"9","author":[{"given":"Edmund A.","family":"Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hsing","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,5,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1586\/14737140.6.10.1341","article-title":"Epratuzumab in the therapy of oncological and immunological diseases","volume":"6","author":"DM Goldenberg","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/11535420-000000000-00000","article-title":"B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data","volume":"70","author":"RJ Looney","year":"2010","journal-title":"Drugs"},{"key":"ref3","first-page":"3","article-title":"The immunological basis of B-cell therapy in systemic lupus erythematosus. Int J Rheum","volume":"13","author":"MY Mok","year":"2010","journal-title":"Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"SV Navarra","year":"2011","journal-title":"Lancet"},{"key":"ref5","first-page":"3982S","article-title":"Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties","volume":"9","author":"J Carnahan","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.molimm.2006.05.007","article-title":"Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab","volume":"44","author":"J Carnahan","year":"2007","journal-title":"Mol Immunol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.4049\/jimmunol.177.5.3063","article-title":"CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo","volume":"177","author":"KM Haas","year":"2006","journal-title":"J Immunol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.4049\/jimmunol.170.7.3534","article-title":"The B cell coreceptor CD22 associates with AP50, a clathrin-coated pit adapter protein, via tyrosine-dependent interaction","volume":"170","author":"B John","year":"2003","journal-title":"J Immunol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1084\/jem.20011783","article-title":"The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound","volume":"195","author":"S Kelm","year":"2002","journal-title":"J Exp Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.4049\/jimmunol.168.12.6078","article-title":"Differentially regulated expression and function of CD22 in activated B-1 and B-2 lymphocytes","volume":"168","author":"F Lajaunias","year":"2002","journal-title":"J Immunol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4049\/jimmunol.172.1.195","article-title":"Cognate B cell signaling via MHC class II: differential regulation of B cell antigen receptor and MHC class II\/Ig-alpha beta signaling by CD22","volume":"172","author":"DM Mills","year":"2004","journal-title":"J Immunol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-065X.2009.00801.x","article-title":"CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions","volume":"230","author":"L Nitschke","year":"2009","journal-title":"Immunol Rev"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.4049\/jimmunol.180.2.907","article-title":"CD22 regulates time course of both B cell division and antibody response","volume":"180","author":"T Onodera","year":"2008","journal-title":"J Immunol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1600-065X.2008.00652.x","article-title":"Regulation of B-cell entry into the cell cycle","volume":"224","author":"S Richards","year":"2008","journal-title":"Immunol Rev"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/1521-4141(200209)32:9<2481::AID-IMMU2481>3.0.CO;2-C","article-title":"CD22 regulates early B cell development in BOB.1\/OBF.1-deficient mice","volume":"32","author":"T Samardzic","year":"2002","journal-title":"Eur J Immunol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.4049\/jimmunol.171.11.6225","article-title":"B-1 B cells mediate required early T cell recruitment to elicit protein-induced delayed-type hypersensitivity","volume":"171","author":"M Szczepanik","year":"2003","journal-title":"J Immunol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2567.2007.02752.x","article-title":"CD22: an inhibitory enigma","volume":"123","author":"JA Walker","year":"2008","journal-title":"Immunology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/hyb.1994.13.469","article-title":"Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma","volume":"13","author":"SO Leung","year":"1994","journal-title":"Hybridoma"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2660::AID-CNCR43>3.0.CO;2-7","article-title":"Generation of a high-producing clone of a humanized anti-B-cell lymphoma monoclonal antibody (hLL2)","volume":"80","author":"MJ Losman","year":"1997","journal-title":"Cancer"},{"key":"ref20","first-page":"2344","article-title":"B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: comment on the editorial by St. Clair and Tedder. Arthritis Rheum","volume":"54","author":"DM Goldenberg","year":"2006"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","article-title":"Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin\u2019s lymphoma","volume":"21","author":"JP Leonard","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1158\/1078-0432.CCR-04-0294","article-title":"Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin\u2019s lymphoma: phase I\/II clinical trial results","volume":"10","author":"JP Leonard","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1200\/JCO.2005.13.821","article-title":"Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin\u2019s lymphoma","volume":"23","author":"JP Leonard","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1038\/sj.onc.1210370","article-title":"Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies","volume":"26","author":"JP Leonard","year":"2007","journal-title":"Oncogene"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/cncr.23890","article-title":"Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma","volume":"113","author":"JP Leonard","year":"2008","journal-title":"Cancer"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children\u2019s Oncology Group Pilot Study","volume":"26","author":"EA Raetz","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2018","article-title":"Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren\u2019s syndrome: an open-label phase I\/II study","volume":"8","author":"SD Steinfeld","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/ar1942","article-title":"Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus","volume":"8","author":"T Dorner","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"ref29","first-page":"1313","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology","volume":"52","author":"DJ Wallace","year":"2013","journal-title":"(Oxford)"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, <etal>et al<\/etal>.. (2013) Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis.","DOI":"10.1136\/annrheumdis-2012-202760"},{"key":"ref31","unstructured":"Wallace D, Kalunian K, Petri M, Strand V, Kilgallen B, <etal>et al<\/etal>.. (2010) Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): Results from EMBLEM\u2122, a phase IIb study. Ann Rheum Dis (suppl 3): 558."},{"key":"ref32","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1182\/blood-2012-12-473744","article-title":"Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab","volume":"122","author":"EA Rossi","year":"2013","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/ni0903-815","article-title":"What is trogocytosis and what is its purpose?","volume":"4","author":"E Joly","year":"2003","journal-title":"Nat Immunol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.4049\/jimmunol.176.4.2600","article-title":"The shaving reaction: rituximab\/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes","volume":"176","author":"PV Beum","year":"2006","journal-title":"J Immunol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/j.1582-4934.2010.01008.x","article-title":"Mechanisms of cellular communication through intercellular protein transfer","volume":"15","author":"KA Ahmed","year":"2011","journal-title":"J Cell Mol Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nri2020","article-title":"Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response","volume":"7","author":"DM Davis","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.febslet.2009.03.014","article-title":"Intercellular exchange of proteins: the immune cell habit of sharing","volume":"583","author":"O Rechavi","year":"2009","journal-title":"FEBS Lett"},{"key":"ref38","first-page":"e8","article-title":"Swapping molecules during cell-cell interactions. Sci STKE","volume":"2005","author":"J Sprent","year":"2005"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/cmi.2008.32","article-title":"Intercellular trogocytosis plays an important role in modulation of immune responses","volume":"5","author":"KA Ahmed","year":"2008","journal-title":"Cell Mol Immunol"},{"key":"ref40","first-page":"20","article-title":"Intercellular exchanges of membrane patches (trogocytosis) highlight the next level of immune plasticity. Transpl","volume":"17","author":"J Caumartin","year":"2006","journal-title":"Immunol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2006-05-024547","article-title":"Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells","volume":"109","author":"J Lemaoult","year":"2007","journal-title":"Blood"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"SB Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/0961203312471574","article-title":"Rituximab treatment in lupus nephritis\u2013where do we stand?","volume":"22","author":"I Gunnarsson","year":"2013","journal-title":"Lupus"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, <etal>et al<\/etal>.. (2013) Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from the randomized, double-blind phase III BELONG study. Arthritis Rheum.","DOI":"10.1002\/art.38037"},{"key":"ref45","first-page":"63","article-title":"Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties. Bioconjug","volume":"24","author":"EA Rossi","year":"2013","journal-title":"Chem"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3109\/10428191003672123","article-title":"Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects","volume":"51","author":"DM Goldenberg","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"ref47","first-page":"5935s","article-title":"Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies","volume":"55","author":"RM Sharkey","year":"1995","journal-title":"Cancer Res"},{"key":"ref48","first-page":"766","article-title":"A new mammalian host cell with enhanced survival enables completely serum-free development of high-level protein production cell lines. Biotechnol. Prog","volume":"27","author":"DL Rossi","year":"2011"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"6161","DOI":"10.1182\/blood-2008-10-187138","article-title":"Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20\/CD22 antibodies in lymphoma","volume":"113","author":"EA Rossi","year":"2009","journal-title":"Blood"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1182\/blood-2010-03-276857","article-title":"Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20\/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias","volume":"116","author":"P Gupta","year":"2010","journal-title":"Blood"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0098315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T16:08:37Z","timestamp":1565453317000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0098315"}},"subtitle":[],"editor":[{"given":"Michael P.","family":"Bachmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,5,19]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0098315","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,19]]}}}